FI3362063T3 - Korkea-annoksisia statiineja silmänpohjan ikärappeumaan - Google Patents
Korkea-annoksisia statiineja silmänpohjan ikärappeumaan Download PDFInfo
- Publication number
- FI3362063T3 FI3362063T3 FIEP16856248.6T FI16856248T FI3362063T3 FI 3362063 T3 FI3362063 T3 FI 3362063T3 FI 16856248 T FI16856248 T FI 16856248T FI 3362063 T3 FI3362063 T3 FI 3362063T3
- Authority
- FI
- Finland
- Prior art keywords
- per day
- dose statin
- patient
- statin
- use according
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims 35
- 206010064930 age-related macular degeneration Diseases 0.000 title claims 8
- 208000002780 macular degeneration Diseases 0.000 title claims 8
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 6
- 229960005370 atorvastatin Drugs 0.000 claims 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 5
- 229960004844 lovastatin Drugs 0.000 claims 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 5
- 229960002855 simvastatin Drugs 0.000 claims 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 5
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 4
- 229960005110 cerivastatin Drugs 0.000 claims 4
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 4
- 229960003765 fluvastatin Drugs 0.000 claims 4
- 229960002797 pitavastatin Drugs 0.000 claims 4
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 4
- 229960002965 pravastatin Drugs 0.000 claims 4
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 4
- 229960000672 rosuvastatin Drugs 0.000 claims 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 238000012423 maintenance Methods 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 108091008695 photoreceptors Proteins 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940100611 topical cream Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241522P | 2015-10-14 | 2015-10-14 | |
| PCT/US2016/056987 WO2017066529A1 (en) | 2015-10-14 | 2016-10-14 | High-dose statins for age-related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3362063T3 true FI3362063T3 (fi) | 2023-04-06 |
Family
ID=58517927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16856248.6T FI3362063T3 (fi) | 2015-10-14 | 2016-10-14 | Korkea-annoksisia statiineja silmänpohjan ikärappeumaan |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11331295B2 (https=) |
| EP (1) | EP3362063B1 (https=) |
| JP (3) | JP7037186B2 (https=) |
| AU (1) | AU2016338540B2 (https=) |
| CA (1) | CA3001661C (https=) |
| DK (1) | DK3362063T3 (https=) |
| ES (1) | ES2941347T3 (https=) |
| FI (1) | FI3362063T3 (https=) |
| IL (1) | IL258604B2 (https=) |
| MX (1) | MX391944B (https=) |
| PH (1) | PH12018500745B1 (https=) |
| WO (1) | WO2017066529A1 (https=) |
| ZA (1) | ZA201803097B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11789024B2 (en) | 2017-05-09 | 2023-10-17 | Massachusetts Eye And Ear Infirmary | Biomarkers for age-related macular degeneration |
| EP3654941A1 (en) * | 2017-07-17 | 2020-05-27 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
| WO2019079515A1 (en) * | 2017-10-17 | 2019-04-25 | Apeliotus Technologies, Inc. | FUNCTIONAL BIOMARKERS FOR STATIN-BASED TREATMENT IN AGE-RELATED MACULAR DEGENERATION (AMD) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030065020A1 (en) * | 2001-07-13 | 2003-04-03 | Catharine Gale | Treatment of macular degeneration |
| CA2478317A1 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| WO2005083430A1 (en) | 2004-02-25 | 2005-09-09 | Massachusetts Eye & Ear Infirmary | Biomarkers for age-related macular degeneration (amd) |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006083533A2 (en) * | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| US20100034749A1 (en) | 2006-07-10 | 2010-02-11 | Medigene Ag | Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases |
| JP2008268506A (ja) * | 2007-04-19 | 2008-11-06 | Fuji Xerox Co Ltd | 現像装置、像保持体ユニットおよび画像形成装置 |
| WO2009023411A1 (en) | 2007-08-09 | 2009-02-19 | Bausch & Lomb Incorporated | Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases |
| US20120156202A1 (en) | 2010-11-05 | 2012-06-21 | Shantha Totada R | Age related macular degeneration treatment |
| EP3041479B1 (en) | 2013-09-06 | 2023-04-26 | Vanda Pharmaceuticals Inc. | Treatment of cyr61- and vegf-mediated conditions |
| WO2016009430A1 (en) | 2014-07-14 | 2016-01-21 | Yeda Research And Development Co. Ltd | Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns |
| MX383117B (es) | 2014-07-31 | 2025-03-13 | Anji Pharmaceuticals Inc | Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma. |
-
2016
- 2016-10-14 CA CA3001661A patent/CA3001661C/en active Active
- 2016-10-14 AU AU2016338540A patent/AU2016338540B2/en active Active
- 2016-10-14 FI FIEP16856248.6T patent/FI3362063T3/fi active
- 2016-10-14 JP JP2018519309A patent/JP7037186B2/ja active Active
- 2016-10-14 WO PCT/US2016/056987 patent/WO2017066529A1/en not_active Ceased
- 2016-10-14 US US15/768,367 patent/US11331295B2/en active Active
- 2016-10-14 DK DK16856248.6T patent/DK3362063T3/da active
- 2016-10-14 EP EP16856248.6A patent/EP3362063B1/en active Active
- 2016-10-14 MX MX2018004636A patent/MX391944B/es unknown
- 2016-10-14 PH PH1/2018/500745A patent/PH12018500745B1/en unknown
- 2016-10-14 IL IL258604A patent/IL258604B2/en unknown
- 2016-10-14 ES ES16856248T patent/ES2941347T3/es active Active
-
2018
- 2018-05-11 ZA ZA2018/03097A patent/ZA201803097B/en unknown
-
2020
- 2020-12-01 US US17/108,065 patent/US11744817B2/en active Active
-
2021
- 2021-09-10 JP JP2021147620A patent/JP7754480B2/ja active Active
-
2023
- 2023-10-13 JP JP2023177353A patent/JP2024016045A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2941347T3 (es) | 2023-05-22 |
| JP2022003042A (ja) | 2022-01-11 |
| EP3362063A4 (en) | 2019-06-19 |
| JP7754480B2 (ja) | 2025-10-15 |
| CA3001661C (en) | 2025-05-06 |
| IL258604A (en) | 2018-06-28 |
| US20210077457A1 (en) | 2021-03-18 |
| US20190209522A1 (en) | 2019-07-11 |
| IL258604B2 (en) | 2024-09-01 |
| MX2018004636A (es) | 2019-06-20 |
| IL258604B1 (en) | 2024-05-01 |
| DK3362063T3 (da) | 2023-04-03 |
| MX391944B (es) | 2025-03-21 |
| EP3362063A1 (en) | 2018-08-22 |
| US11331295B2 (en) | 2022-05-17 |
| EP3362063B1 (en) | 2023-01-11 |
| NZ742203A (en) | 2025-06-27 |
| US11744817B2 (en) | 2023-09-05 |
| PH12018500745B1 (en) | 2023-03-15 |
| JP2024016045A (ja) | 2024-02-06 |
| CA3001661A1 (en) | 2017-04-20 |
| ZA201803097B (en) | 2022-12-21 |
| JP7037186B2 (ja) | 2022-03-16 |
| JP2018530586A (ja) | 2018-10-18 |
| PH12018500745A1 (en) | 2018-10-15 |
| WO2017066529A1 (en) | 2017-04-20 |
| AU2016338540B2 (en) | 2022-04-28 |
| AU2016338540A1 (en) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| RU2019134341A (ru) | (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства | |
| MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
| WO2011106729A3 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| MX2020009235A (es) | Formulacion oftalmica. | |
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| MX2016002178A (es) | Composiciones y metodos terapeuticos para la regresion acelerada de placa. | |
| FI3362063T3 (fi) | Korkea-annoksisia statiineja silmänpohjan ikärappeumaan | |
| MX2015012653A (es) | Formulaciones oculares para suministro de farmaco al segmento porterior del ojo. | |
| IL292829A (en) | Fixed dose combinations containing etc1002 and one or more statins to treat or reduce cardiovascular risk | |
| EP4342473A3 (en) | Compounds useful in hiv therapy | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| JP2022003042A5 (https=) | ||
| EP2819741A4 (en) | SOLVENT MEDICINAL IMPLANTS FOR THE INTRACOCHLEAR RELEASE OF THERAPEUTICS FOR THE TREATMENT OF EARLIER DISEASES | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| JP2018530586A5 (https=) | ||
| EP3570835A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF IMMUNINFLAMMABLE DERMAL DISEASES | |
| MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| WO2009133552A3 (en) | Methods of treating ophthalmic disorders | |
| TN2019000063A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| FR2974300B1 (fr) | Utilisation d'une combinaison d'un carotenoide, d'un phytoestrogene et de la vitamine c pour la prevention et/ou le traitement de desordres pigmentaires | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti |